Cargando…
Tumor-targeted delivery of a STING agonist improves cancer immunotherapy
The cGAS-STING pathway is essential for immune defense against microbial pathogens and malignant cells; as such, STING is an attractive target for cancer immunotherapy. However, systemic administration of STING agonists poses safety issues while intratumoral injection is limited by tumor accessibili...
Autores principales: | Wu, You-tong, Fang, Yan, Wei, Qi, Shi, Heping, Tan, Huiling, Deng, Yafang, Zeng, Zhiqun, Qiu, Jian, Chen, Chuo, Sun, Lijun, Chen, Zhijian J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894229/ https://www.ncbi.nlm.nih.gov/pubmed/36442099 http://dx.doi.org/10.1073/pnas.2214278119 |
Ejemplares similares
-
Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy
por: Zheng, Huan, et al.
Publicado: (2022) -
Overcoming challenges in the delivery of STING agonists for cancer immunotherapy: A comprehensive review of strategies and future perspectives
por: Huang, Cuiqing, et al.
Publicado: (2023) -
Co-delivery of phagocytosis checkpoint and STING agonist by a Trojan horse nanocapsule for orthotopic glioma immunotherapy
por: Zhou, Ying, et al.
Publicado: (2022) -
Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I–deficient and MHC I(+) tumors
por: Wolf, Natalie K., et al.
Publicado: (2022) -
Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy
por: Motedayen Aval, Leila, et al.
Publicado: (2020)